[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100587427":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":32,"locations":42,"responsibleParty":78,"collaborators":82,"id":86,"slug":24,"hasResults":87,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":87,"sex":93,"minAge":94,"maxAge":24,"enrollmentInfo":95,"targetDuration":24,"studyType":98,"phases":99,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":66,"whyStopped":24,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},{"fullName":5,"class":6},"University of Pittsburgh","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Onabotulinum Toxin Type A - Phase 1b","EXPERIMENTAL","Onabotulinum toxin administered to two lesions.",[13],"Drug: Onabotulinum Toxin Type A - Phase 1b",{"label":15,"type":10,"description":16,"interventionNames":17},"Onabotulinum Toxin Type A - Phase 2","Onabotulinum toxin administered to three lesions.",[18],"Drug: Onabotulinum Toxin Type A - Phase 2",[20,25],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","The lesions receiving Botulinum toxin will get five 0.1 mL intradermal injections of 5 units of Botulinum toxin which equates to 25 units per lesion and 50 units per patient.",[9],null,{"type":21,"name":15,"description":26,"armGroupLabels":27,"otherNames":24},"The lesions receiving Botulinum toxin will get five 0.1 mL intradermal injections of 5 units of Botulinum toxin which equates to 25 units per lesion and 75 units per patient.",[15],[29],{"name":30,"affiliation":5,"role":31},"Daniel Kaplan, MD, PhD","PRINCIPAL_INVESTIGATOR",[33,38],{"name":34,"role":35,"phone":36,"phoneExt":24,"email":37},"Charity Ruhl, LPN","CONTACT","4126472013","ruhlcl@upmc.edu",{"name":39,"role":35,"phone":40,"phoneExt":24,"email":41},"Anna Davis, MD","4126475633","davisa60@upmc.edu",[43,64],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"University of Pittsburgh Medical Center","NOT_YET_RECRUITING","Pittsburgh","Pennsylvania","15213","United States",{"type":51,"coordinates":52},"Point",[53,54],-79.99589,40.44062,{"lat":54,"lon":53},[57,58,59,61],{"name":39,"role":35,"phone":40,"phoneExt":24,"email":41},{"name":34,"role":35,"phone":36,"phoneExt":24,"email":37},{"name":60,"role":31,"phone":24,"phoneExt":24,"email":24},"Daniel H Kaplan, MD, PhD",{"name":62,"role":63,"phone":24,"phoneExt":24,"email":24},"Joe K Tung, MD, MBA","SUB_INVESTIGATOR",{"facility":65,"status":66,"city":46,"state":47,"zip":48,"country":49,"cosmosGeoPoint":67,"geoPoint":69,"contacts":70},"UPMC Department of Dermatology","RECRUITING",{"type":51,"coordinates":68},[53,54],{"lat":54,"lon":53},[71,75,76],{"name":72,"role":35,"phone":73,"phoneExt":24,"email":74},"Neethi Francis, MA","4126474023","francisn2@upmc.edu",{"name":34,"role":35,"phone":40,"phoneExt":24,"email":37},{"name":77,"role":63,"phone":24,"phoneExt":24,"email":24},"Joe Tung, MD, MBA",{"type":79,"investigatorFullName":80,"investigatorTitle":81,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"SPONSOR_INVESTIGATOR","Daniel Kaplan","Professor",[83],{"name":84,"class":85},"Almirall, S.A.","INDUSTRY","100587427",false,"NCT06928246","The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis","Pilot Study on Cellular and Molecular Impact of Neuroimmune Interactions in Atopic Dermatitis","AD","Inclusion Criteria:\n\nPhase 1b:\n\n* Patients 18 years or older at time of consent\n* Mild-to-Moderate AD, defined as:\n* BSA ≤ 10%\n* IGA ≤ 3\n* No past biologic therapy\n* No systemic therapy for 3 months\n* No topical therapy for treatment of AD for 4 weeks\n\nPhase 2:\n\n* Patients 18 years or older at time of consent\n* Mild-to-Moderate AD, defined as:\n* BSA ≤ 10%\n* IGA ≤ 3\n* At least one patch of eczema of at least 5 cm in diameter\n* No past biologic therapy\n* No systemic therapy for 3 months\n* No topical therapy for treatment of AD for 4 weeks\n\nExclusion Criteria:\n\nPhase 1b:\n\n* Age less than 18 years old\n* Pregnant or breastfeeding\n* Has medical comorbidity such as end stage congestive heart failure or coagulopathy that is a relative contradiction to skin biopsy procedure\n* Has had prior exposure to biologic treatments or has had prior treatment with systemic non-biologics (e.g. methotrexate) within 12 weeks\n* Has used topical therapy for treatment of AD within 4 weeks\n\nPhase 2:\n\n* Patients enrolled in Phase 1\n* Age less than 18 years old\n* Pregnant or breastfeeding\n* Has medical comorbidity such as end stage congestive heart failure or coagulopathy that is a relative contradiction to skin biopsy procedure\n* Has had prior exposure to biologic treatments or has had prior treatment with systemic non-biologics (e.g. methotrexate) within 12 weeks\n* Has used topical therapy for treatment of AD within 4 weeks","ALL","18 Years",{"count":96,"type":97},8,"ESTIMATED","INTERVENTIONAL",[100],"PHASE1","The purpose of this study is to understand cellular and molecular interactions in the skin of participants with mild-to-moderate AD, and how botulinum toxin alters these interactions.",[103],"Atopic Dermatitis (AD)",[105,106,107],"Atopic dermatitis","Eczema","Botox","2026-05-01",{"date":110,"type":111},"2026-05-04","ACTUAL",{"date":113,"type":111},"2025-07-17",{"date":115,"type":97},"2027-01",{"name":80,"class":6},2]